See also this year's filing and all EDGAR filings for this company.
PDF Report 0000874015_2022_Ionis_Pharmaceuticals_INC.pdf
Logs
| warning | Large missing amount for aggregate "Liabilities" added to remainder. | industry.us_generic | {'missing_ratio': 1.7117152036785945, 'aggregate_val': 1839953000, 'exp_sum': 678520000, 'exp_to_value': {'LiabilitiesCurrent': 240550000, 'LiabilitiesNoncurrent': 351879000, 'remainder_Liabilities': 86091000}} |
| warning | Large missing amount for aggregate "Liabilities" added to remainder. | industry.us_generic | {'missing_ratio': 1.4690038187305396, 'aggregate_val': 1960989000, 'exp_sum': 794243000, 'exp_to_value': {'LiabilitiesCurrent': 311561000, 'LiabilitiesNoncurrent': 473835000, 'remainder_Liabilities': 8847000}} |
Graph
Absolute values for 0000874015, Ionis Pharmaceuticals INC
| xvar | xval | |
|---|---|---|
| 0 | AssetsCurrent | 2,345,049,000 |
| 1 | IntangibleAssetsNetIncludingGoodwill | 29,005,000 |
| 2 | PropertyPlantAndEquipmentNet | 178,069,000 |
| 3 | remainder_Assets | 59,567,000 |
| 4 | LiabilitiesCurrent | 240,550,000 |
| 5 | LiabilitiesNoncurrent | 351,879,000 |
| 6 | remainder_Liabilities | 1,247,524,000 |
| 7 | CostOfGoodsAndServicesSold | 10,504,596 |
| 8 | SellingGeneralAndAdministrativeExpense | 139,479,303 |
| 9 | ResearchAndDevelopmentExpense | 0 |
| 10 | remainder_Expenses | 673,216,168 |
| 11 | remainder_Revenues | 790,983,296 |
| 12 | remainder_NetIncome | 24,409,841 |
| 13 | remainder_ComprehensiveNetIncome | 10,029,096 |
| yvar | yval | |
|---|---|---|
| 0 | Assets | 2,611,690,000 |
| 1 | Liabilities | 1,839,953,000 |
| 2 | Expenses | 823,200,067 |
| 3 | Revenues | 790,983,296 |
| 4 | StockholdersEquity | 771,737,000 |
| 5 | NetIncome | -7,806,930 |
| 6 | ComprehensiveNetIncome | -2,792,382 |
| 7 | BaseVar | 3,050,132,650 |
| 8 | EconomicCapitalRatiobeforeLimitedLiability | 0.755 |
| 9 | EconomicCapitalRatio | 2.10 |
Edgar->Model Mapping
Feature Distribution
Change over Time
